Biomunex announces the clinical development of a new therapeutic class in oncology
IPN60330 is a bispecific antibody engaging MAIT cells, a subset of non-conventional T cells present throughout the body, and the clinically validated tumor antigen GPC3 to kill cancer cells across a variety of solid tumors
























